Scaling early subclinical RHD screening across rural India by augmenting frontline health networks — ASHA workers, ANMs, and RBSK mobile health teams — with zero-cap-ex AI software that runs on existing Bluetooth stethoscopes.
RHD remains one of the most preventable causes of pediatric cardiac mortality in South Asia. Our platform is engineered to integrate directly into the screening infrastructure already mandated by the Government of India and the WHO.
Plugs directly into India's Rashtriya Bal Swasthya Karyakram under the National Health Mission, closing the gap in mandatory school health screening for children aged 5–15[1].
Designed for rural deployment by ASHA workers and community health officers, matching the secondary prevention objectives demonstrated by the ICMR Jai Vigyan Mission Mode Project[2].
Directly addresses the WHO regional mandate to accelerate the prevention and control of cardiovascular morbidity — tackling the reality that India carries a disproportionate share of the global RHD burden[3][4].
A complete on-device pipeline — patient triage, real-time auscultation capture, AI risk stratification, and structured specialist hand-off — built for community health workers and primary-care clinicians.
Hardware-agnostic software licensing — priced per screened child, not per device — aligned to state health budget cycles and donor-funded program economics.
Alleviating a Multi-Billion Dollar National Capital Drain Through Precision AI Surveillance.
Independent cost-of-illness modeling shows that Rheumatic Heart Disease (RHD) costs India over $10.7 Billion (USD) annually due to combined direct medical treatments and lost workforce productivity from premature mortality.
Sourced from peer-reviewed cost-of-illness models estimating direct medical expenditure (outpatient, inpatient, surgery, drugs) and indirect costs (premature mortality, DALYs, caregiver burden) across India's public and private health systems. Cross-referenced with ICMR national disease burden estimates and WHO SEARO cardiovascular disease cost reports. Assumes USD/INR exchange rate of ~83 for conversion consistency.
Academic hospital cost analyses confirm that RHD demands the highest treatment expenditure and longest hospital stays (median 11 days) among all major cardiovascular diseases in India.
Median inpatient stay derived from tertiary hospital cost-analysis studies across Indian metropolitan cardiac centers, comparing CVD admission lengths. Assumes hospitalization includes pre-operative evaluation, open-heart surgery (valve repair/replacement), and post-operative ICU recovery. Excludes recurrent admissions for the same patient within the measurement window.
The World Health Organization (WHO) estimated that India spent over $236 Billion managing chronic cardiovascular diseases over a 10-year period — a burden heavily driven by late-stage, tertiary critical care.
Aggregated from WHO Noncommunicable Diseases Country Profiles and World Bank health expenditure data for India (2011–2021). Includes direct government health spending, out-of-pocket private expenditure, and insurance claims on hypertension, coronary artery disease, stroke, and RHD. Assumes inflation-adjusted constant USD (2021 base year) and includes both urban and rural populations.
Subsidized open-heart valve replacement surgeries strain state budgets at ₹2 Lakhs to ₹6 Lakhs per patient. By scaling early acoustic screening via the RBSK and National Health Mission framework, states can catch subclinical cases early. Early secondary prophylaxis costs under ₹1,500 annually — cutting public outlays exponentially.
Surgical cost range (₹2L–₹6L) based on NHM reimbursement schedules for tertiary cardiac procedures in empanelled government hospitals and PM-JAY package rates. Secondary prophylaxis cost (penicillin benzathine + clinic visits) derived from RBSK operational guidelines and state health mission procurement tenders. Assumes 80% treatment adherence in screened cohorts and excludes transport/logistics subsidies.
End-stage RHD forces long, resource-intensive inpatient stays that tie up critical cardiac ICU beds. Shifting the patient pipeline toward automated outpatient acoustic tracking increases general hospital throughput, lowers administrative overhead, and optimizes bed allocation for high-turnover procedures.
Bed-day impact modeled from Indian tertiary cardiac center admission data, assuming average 11-day RHD stays vs. 2-day elective outpatient turnover. Administrative overhead savings assume 30% reduction in emergency triage paperwork and referral coordination when cases are captured in the community. Assumes hospital maintains baseline surgical capacity and does not account for capital expansion costs.
Early detection across corporate, family, and pediatric insurance pools stops mild murmurs from cascading into catastrophic heart failure events. By identifying issues before surgical thresholds are hit, private insurers mitigate severe high-severity claims and stabilize overall premium risk pools.
"Up to 90% claims reduction" is a modeled ceiling based on shifting late-stage surgical events (₹5L+ claims) to early-stage prophylaxis (₹1,500–₹5,000 annual claims) across actuarial scenarios. Derived from Indian health insurance claims data for pediatric and young-adult cardiac pools. Assumes 60–70% screening coverage in the insured population and 2–3 year detection-to-treatment lag. Not a guaranteed outcome; represents best-case prevention economics.
Instead of a single, often fatal critical care episode, pharmaceutical deployment transforms into a steady, long-term supply chain. Early diagnosis secures decades-long patient adherence to high-volume, continuous secondary prophylaxis and cardiac maintenance regimens.
"Decade-long lifecycle" assumes patient diagnosed at age 10–12 and maintained on secondary prophylaxis (penicillin benzathine G, 1.2 MU IM every 3–4 weeks) through age 25–30 per WHO RHD prevention protocols. Pharmaceutical volume modeled from standard prophylaxis dosing schedules plus ancillary cardiac medications (diuretics, ACE inhibitors, anticoagulants) for moderate-to-severe cases. Assumes 75% long-term adherence and generic drug pricing benchmarks.
Detailed financials, clinical validation roadmap, deployment pipeline with state health partners, and Series A allocation — available to qualified institutional investors.